. Author manuscript; available in PMC: 2014 May 2.

Published in final edited form as: Cancer. 2012 Jan 17;118(18):4597–4605. doi: 10.1002/cncr.27414

Table 1.

North American Cooperative Group Trials Onto Which Patients Included in This Study Were Enrolled

Study	Cooperative Group	Eligibility		Treatment Arms
		Metastatic Disease	Unresectable Disease
INT-0133	CCG	Allowed	Allowed	MAP
	POG	No	No	MAP + MTPPE
				MAP + IFOS
				MAP + MTPPE + IFOS
CCG-7943	CCG	Required^a	Allowed	TOPO + ICE + AP
POG-9754	POG	No	No	MAP
				MAP, high A
				MAP + IFOS
				MAPIE
AOST0121	COG	Required^b	Allowed	MAP
				MAPIE + trastuzumab

Abbreviations: AP, doxorubicin and cisplatin; CCG, Children's Cancer Group; COG, Children's Oncology Group; high A, higher cumulative dose doxorubicin (up to 600 mg/m²); ICE, ifosfamide, carboplatin, and etoposide; IFOS, ifosfamide; MAP, high-dose methotrexate, doxorubicin, and cisplatin; MAPIE, MAP plus ifosfamide and etoposide; MTPPE, muramyl tripeptide phosphatidyl ethanolamine; POG, Pediatric Oncology Group; TOPO, topotecan.

Unresectable pulmonary metastases with ≥5 nodules and/or disease involving multiple bones or other organs.

Bone metastases ± lung metastases, or bilateral lung metastases, or unilateral lung metastases with ≥4 nodules.